[DATE]

COVID -19 PLAN

[DOCUMENT SUBTITLE]

Disclaimer: This template document, developed for the PR-BEOC and the PR Economic Advisory Board, is intended to provide general guidance on COVID-19 risk factors and non-pharmaceutical interventions measures as described in the available Centers for Disease Control and Prevention (CDC) Guidelines, PROSHA Guidelines and World Health Organization (WHO) public documents as of April, 21 2020. This template is not intended to provide medical guidelines or address medical concerns or specific risk circumstances and is not a substitute for professional medical advice, diagnosis or treatment. The information contained within is gathered and shared from reputable sources; however, DGF Consulting Group is not
responsible for errors or omissions in reporting or in any conclusion put forth by any of such sources. This template is not intended to provide specific recommendations for the PR-BEOC or the PR Economic Advisory Board to follow. Due to the dynamic nature of infectious diseases, DGF Consulting Group, its parent company, affiliates, subsidiaries and other officers, directors, and employees cannot be held liable for the use, reference to, or reliance on the template provided. We strongly encourage PR-BEOC and the PR Economic Advisory Board, the Business Community and the Organizations in Puerto Rico to continuously seek the assistance of a professional to adapt, and adopt this template to its business, as well as to continuously seek additional safety, medical, and epidemiologic information from credible sources such as the CDC, Puerto Rico Department of Health, PROSHA, OSHA and the WHO.

COVID-19 PLAN

TABLE OF CONTENTS

DISCLOSURE	3
ABOUT COVID-19	4
SYMPTOMS	4
HOW COVID-19 SPREADS	5
COVID-19 PLAN	5
INCIDENT MANAGEMENT PLAN	14
COMMUNICATION PLAN	14
SUCCESSION PLAN	10
EFFECTIVE DATE	14
APPROVED BY	15
APPENDIX 1	16
APPENDIX 2	
APPENDIX 3	

DISCLOSURE

ABOUT COVID-19

Coronaviruses are a large family of viruses that may cause illness in humans or animals. In humans, several coronaviruses are known to cause respiratory infections ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The most recently discovered coronavirus causes coronavirus disease COVID-19. Coronaviruses are single strand enveloped RNA virus belonging to the family of *Coronaviridae* of zoonotic origin.

COVID-19 is the clinical syndrome associated with SARS-CoV-2 infection, which is characterized by a respiratory syndrome with a variable degree of severity, ranging from a mild upper respiratory illness to severe interstitial pneumonia and Acute Respiratory Distress Syndrome (ARDS). Coronaviruses are named for the crown appearance on electron microscopy. There are four genera of the coronaviruses, known as alpha, beta, gamma, and delta. The SARS-CoV-2 virus is a betacoronavirus, like MERS-CoV and SARS-CoV.

SYMPTOMS

According to the Centers for Disease Control and Prevention CDC, generalized symptoms may appear 2-14 days after exposure .

- Cough
- Shortness of breath or difficulty breathing

Or at least two of these symptoms

- Fever
- Chills
- · Repeated shaking with chills
- Muscle pain
- Headache
- Sore throat
- New loss of taste or smell

In addition to the symptoms presented in the CDC guidelines, WHO also includes tiredness as a common symptom. Other symptoms reported may include diarrhea, abdominal pain, severe vomiting and neurological changes. The list of symptoms is not all-inclusive; therefore, CDC and WHO recommends consulting a medical provider for any symptoms of concern.

HOW COVID-19 SPREADS

According to CDC guidelines and the PR Department of Health available information as of the date of the approval of this guideline, COVID-19 is thought to be spread mainly from person to person.

- Between people who are in close contact with one another (within about 6 feet).
- Through respiratory droplets produced when an infected person coughs, sneezes, or talks that can land in the mouths or noses of people who are nearby or possibly be inhaled into the lungs.

It may be possible that a person can get COVID-19 by touching a surface or object that has SARS-CoV-2 on it and then touching their mouth, nose, or possibly their eyes, but this is not thought to be the primary way the virus spreads.

Viral shedding by asymptomatic people may represent 25–50% of total infections.

- Viral shedding may antedate symptoms by 1–2 days.
- Viral titers are highest in the earliest phases of infection.

COVID-19 PLAN

Scope:

To define specific mitigation measures adopted by:

COMPANY NAME

to mitigate COVID-19 potential employee exposure risks related to workplace activities.

This plan is specific to the facility located at:

PHYSICAL ADDRESS

Operating Plan
Working Days
Monday - Friday
Monday-Sunday
Other
Number of Shifts
Shifts
Operational Schedules
Shift 1
Shift 2
Shift 3
Shift 4
Other
Total Employees per Shift
Shift 1
Shift 2
Shift 3
Shift 4

Employees Working from Home by Shift	
Shift 1	
Shift 2	
Shift 3	
Shift 4	
COMPANY NAME	
Maintains an actualized list of all employees. Employees listed are classified as	
a. working remotelyb. active (employees not working from home or remotely).	
COMPANY NAME	
Completed an assessment considering the COVID-19 risk factors included in the current PROSHA and CDC Guidelines as of the effective date of this plan.	
Mitigation and Control Dian.	
Mitigation and Control Plan:	
COMPANY NAME	
COMPANY NAME Adopted and implemented the following measures to mitigate COVID-19 risks identified as a	
COMPANY NAME Adopted and implemented the following measures to mitigate COVID-19 risks identified as a result of the risk assessment process. Table 1: Workforce Related Measures DESCRIPTION	
COMPANY NAME Adopted and implemented the following measures to mitigate COVID-19 risks identified as a result of the risk assessment process. Table 1: Workforce Related Measures	
COMPANY NAME Adopted and implemented the following measures to mitigate COVID-19 risks identified as a result of the risk assessment process. Table 1: Workforce Related Measures DESCRIPTION Employee Related Controls	
COMPANY NAME Adopted and implemented the following measures to mitigate COVID-19 risks identified as a result of the risk assessment process. Table 1: Workforce Related Measures DESCRIPTION Employee Related Controls	

Client Exposure Risks	
Other Risks	
Surveillance, Hygiene and PPE	
Controls Employee Surveillance (Monitoring)	
Employee Surveillance (Monitoring) Controls	
Employee PCR Testing for COVID-19 Plan	
Use of personal of mask in addition to required Personal Protection	
Equipment (PPE)	
Personal Hygiene Practices	
Other	

Physical Social Distancing

Table 2 Physical Social Distancing Measures

	DESCRIPTION
Work layouts modifications	
Dhysical suggestion	
Physical areas demarcation	
Physical barriers	
Has af about descriptions at	
Use of shared equipment	
(telephones, chairs, working tables) modifications	
modifications	
Work hours modifications	
Flexible work plan modifications (ex. work from home)	
(ex. work from nome)	
Common areas layouts	
modifications	
Use of Common Areas	

Other	

Environmental and Engineering Measures

Table 3 Environmental and Engineering Measures

Environmental and Engineering Measures	
HVAC Modifications	
Contact Surfaces Cleaning, Concurrent Disinfection Protocol	
Sanitation Protocol	
Samuelon Frotoco.	
Other	

Administrative Controls

Table 4 Administrative Controls

	DESCRIPTION
COVID-19 Illness Notification	
Protocol	
COVID-19 Employee Surveillance	
Protocol	
COVID-19 Person Under	
Investigation Isolation Protocol	
COVID -19 Management of Breaks	
and Food Periods	
COVID -19 Use of Common Areas	
Protocol	
COVID -19 Risk Notification Protocol	
COVID 10 Posniratory Etiquetta	
COVID -19 Respiratory Etiquette Protocol	
FIOLOCOI	
COVID -19 Hand Washing	
Techniques Protocol	
reemingues i rotocoi	

COVID-19 Use of PPE Protocol	
COVID-19 Workforce Contact Tracing Program	
Other	

GOIDELINE
HIGH
MEDIUM
LOW
INCIDENT MANAGEMENT PLAN
COMPANY NAME
Incident Management Plan is included in Appendix 1.
COMMUNICATIONS PLAN
COMPANY NAME
COVID-19 Communications Plan is included in Appendix 2.
TRAINING
COMPANY NAME
COVID-19 Training Evidence is included in Appendix 3.
EFFECTIVE DATE
Effective date
Revision number

COVID 19 RISK CLASSIFICATION AS PER PROSHA 3990-03-2020

APPROVED BY

Signature			
Tittle			
Date			

APPENDIX 1: INCIDENT MANAGEMENT PLAN

APPENDIX 2: COMMUNICATIONS PLAN

APPENDIX 3: TRAINING EVIDENCE

APPENDIX 4: SUCCESSION PLAN